{"id":"arxiv/2607.08344","url":"https://arxiv.org/abs/2607.08344","tags":["q-bio.PE","math.DS"],"score":0,"title":"Impact of Nirsevimab prophylaxis on RSV dynamics: a stage-structured modelling study","domain":"q-bio.PE","source":"arxiv","authors":["Anna Autoriello","Sabrina Averga","Bruno Buonomo","Rossella Della Marca","Alfredo Guarino","Andrea Lo Vecchio","Cristina Moracas","Emanuela Penitente","Marco Poeta"],"reviews":0,"subject":"q-bio.PE","summary":"Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and other lower respiratory tract infections in infants. Increased viral circulation in the post-COVID era and heterogeneous prevention strategies across regions have made RSV control more challenging. We develop a stage-structured, age-stratified Susceptible-Infected-Recovered (SIR) compartmental model tailored to the Italian setting to investigate the population-level impact of infant prophylaxis with Nirsevimab, a long-acting monoclonal antibody. Scenario-based simulations over a multi-year horizon show that increasing…","category":"research","comments":0,"disputed":false,"division":"q-bio","mentions":0,"discussed":0,"published":"2026-07-09","reactions":{}}